Quest For Growth

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

Finquest is a leading deal origination provider that specializes in delivering personalized connections for clients seeking mergers and acquisitions (M&A) and direct investment opportunities across Europe, North America, and the Asia-Pacific region. Utilizing a unique database and advanced machine learning techniques, Finquest offers targeted and curated introductions, facilitating a more efficient deal-making process while ensuring complete confidentiality. The company's platform focuses on the middle market, connecting institutional investors with potential investment opportunities and enabling corporate buyers to identify relevant acquirers. Headquartered in Singapore, Finquest operates offices in key financial centers including New York, Dallas, London, Paris, Frankfurt, Luxembourg, Bangalore, and Hong Kong, broadening market access for its clients.

Qpinch is a company focused on transforming wasted industrial heat into valuable process heat, thereby generating carbon-neutral steam and reducing energy costs for various industries. By utilizing an innovative chemical heat transformer, Qpinch helps businesses optimize their existing industrial assets, leading to immediate energy savings while minimizing their environmental impact. The company's technology allows clients to effectively repurpose waste heat, contributing to a more sustainable energy landscape and enhancing operational efficiency.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, offering comprehensive solutions for tracking and monitoring these items through advanced wireless technology. Founded in 2013 and based in Ghent, Belgium, the company combines expertise in low-power networks and wireless sensor design to deliver innovative tracking systems, including their personal product line, STICKNTRACK. Sensolus provides a cloud-based platform that enables users to access real-time information about their assets, making the management of valuable equipment in industries such as manufacturing, waste management, cargo transport, logistics, and automotive efficient and straightforward. Their offerings focus on affordable, easy-to-install, and maintenance-free tracking solutions, ensuring seamless asset management for users.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

Miracor Medical is a medical device company that specializes in developing clinical devices aimed at treating severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company is known for its PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion technology. This innovative system is designed to assist cardiac surgeons in treating patients experiencing myocardial infarction during coronary artery bypass grafting procedures. By enhancing microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size, improve cardiac function, and potentially decrease the likelihood of heart failure following acute myocardial infarction.

HalioDx is a biotechnology company focused on developing diagnostic tests for oncology that analyze the immune contexture of cancers. The company creates a range of immunologic scoring tests aimed at investigating the immune response within the tumor microenvironment. These tests leverage a proprietary set of immune biomarkers and advanced image analysis technologies to accurately measure the immune reaction in and around tumors. By providing insights into the severity of a patient's disease and predicting their response to treatment, HalioDx seeks to enhance clinical decision-making and improve patient outcomes in cancer care.

Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, offering comprehensive solutions for tracking and monitoring these items through advanced wireless technology. Founded in 2013 and based in Ghent, Belgium, the company combines expertise in low-power networks and wireless sensor design to deliver innovative tracking systems, including their personal product line, STICKNTRACK. Sensolus provides a cloud-based platform that enables users to access real-time information about their assets, making the management of valuable equipment in industries such as manufacturing, waste management, cargo transport, logistics, and automotive efficient and straightforward. Their offerings focus on affordable, easy-to-install, and maintenance-free tracking solutions, ensuring seamless asset management for users.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.

Cartagenia is a provider of software and services designed for clinical genetics and molecular pathology laboratories. The company offers a specialized software platform that facilitates the assessment and reporting of clinical genomics data derived from next-generation sequencing and microarrays. This platform enables technicians, lab directors, and clinicians to visualize and evaluate genetic variants in the context of patient information, thereby streamlining the process of conducting clinically relevant genetic analyses. By delivering expert systems and services, Cartagenia supports genetic labs and healthcare professionals in providing high-quality genetic interpretation and counseling to patients and their caregivers.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled respiratory medicines for conditions such as asthma and chronic obstructive pulmonary disease. Established in 2006, Prosonix specializes in generic mono and combination therapies that utilize inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. The company employs proprietary ultrasonic particle engineering technologies to create and optimize drug formulations, enhancing the delivery and effectiveness of its inhaled medications. Prosonix is recognized for its innovative approach to developing new methods for transforming molecules into particles suitable for inhalation, allowing for tailored therapeutic solutions. As of June 2015, Prosonix operates as a subsidiary of Circassia Limited.

Anteryon International, established in 2006, specializes in designing, manufacturing, and distributing high-precision optical components. Its product portfolio includes a wide range of lenses, laser modules, optical mirrors, filters, and custom opto-mechatronic assemblies. Serving diverse sectors such as medical, telecom, defense, and semiconductor industries, the company leverages its patented replication and opto-mechanical assembly technology, along with deep domain expertise, to deliver standard and customer-specific optical solutions. Headquartered in Eindhoven, the Netherlands, Anteryon International operates as a subsidiary of China Wafer Level CSP Co., Ltd.

Active Circle is a company that develops and markets innovative software solutions for storage and archive management, specifically tailored for organizations handling large volumes of digital content. Its offerings enable clients to effectively store, preserve, and manage various types of files, including video content, images, and scientific and technical data. By providing tools that help organizations control the lifecycle of their data, Active Circle aids in reducing storage costs and enhancing data management efficiency.

CoreOptics is a prominent manufacturer of advanced subsystems designed for high-speed optical networking applications in the telecommunications and information technology sectors. The company specializes in 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, catering to Metro, Regional, and Long Haul optical and data networking markets. CoreOptics advocates for open systems in optical communications networks, enabling efficient data transmission regardless of data rates or fiber types. Their innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is the only field-proven solution available, empowering Tier 1 systems vendors and carriers to enhance their high-performance networks using existing fiber infrastructure. By eliminating the need for Optical Compensators and associated Second Stage Amplifiers, CoreOptics' products can significantly reduce initial deployment costs for customers, making them a valuable partner in the evolution of optical networking.

iNEWiT is an engineering company based in Mechelen, Belgium, founded in 2005. It specializes in identifying, designing, and creating applications and devices tailored for the mobile market. The company develops mobile video communication applications utilizing its patent-pending technology to transmit data, video, and sound across various wireless and wired platforms. iNEWiT also offers wireless communication technologies that encompass GPRS/EDGE, 3G, HSDPA/HSUPA, WiFi, WiMAX, and satellite networks. Additionally, it provides plug-and-play products aimed at the business-to-consumer markets.

Certess is an electronic design automation (EDA) company that specializes in functional qualification products aimed at organizations developing and integrating complex design blocks or intellectual property (IP). Founded in 2005 and based in Campbell, California, the company addresses a critical gap in the verification process by offering tools that help design and verification engineers objectively assess and enhance the completeness of their verification environments. Despite the use of various techniques by verification teams, functional logic errors frequently lead to chip respins, underscoring the need for Certess's innovative solutions. By improving verification quality, Certess's software contributes to a more efficient and predictable integration process for system-on-chip (SoC) designs, ultimately ensuring higher quality outcomes. In March 2009, Certess was acquired by SpringSoft, LLC.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

MAPPER Lithography B.V. is a company specializing in the development of maskless lithography infrastructure for the semiconductor industry. Established in 2000 and headquartered in Delft, the Netherlands, MAPPER Lithography focuses on producing advanced lithography machines that utilize multiple electron beam technology for semiconductor manufacturing. This innovative approach allows for the production of chips without the need for traditional masks, streamlining the manufacturing process. The company also operates a manufacturing facility in Moscow, Russian Federation, further supporting its operations in the semiconductor sector.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. Founded in 2006 and headquartered in Turnhout, Belgium, Movetis focuses on conditions such as severe chronic constipation, ascites, pediatric reflux, and complex GI motility disorders like refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is specifically developed for the symptomatic treatment of chronic constipation in women, with ongoing research to extend its use to males, children, and conditions like opioid-induced constipation and postoperative ileus. Movetis is also advancing other candidates in its pipeline, including M0002, currently in Phase II trials for ascites, and M0003, which is entering Phase II development for treating heartburn and pediatric reflux in patients resistant to proton pump inhibitors. Additionally, the company has prioritized compounds from its preclinical portfolio and maintains partnerships with several academic institutions in Belgium and the Netherlands to enhance its research capabilities.

Plastic Logic Ltd is a manufacturer of plastic electronics, specializing in the development and production of flexible displays and devices. The company, based in Cambridge, United Kingdom, and with operations in Dresden, Germany, offers a range of high-quality, lightweight, and shatterproof electrophoretic displays in both color and monochrome. These displays are utilized in various applications, including mobile devices such as smartphones, e-readers, and tablets, as well as in signage, wristwatches, and automotive products. Plastic Logic serves original equipment manufacturers (OEMs), system integrators, and device manufacturers across the UK, Germany, Russia, and other international markets. The company has established a strategic partnership with UST Global Inc. and operates a pioneering facility that serves as the world's first commercial, volume production site for organic electronics. Through its open pilot line, Plastic Logic also collaborates with third-party companies, sharing its expertise in the industrialization and manufacturing of flexible electronics.

CoreOptics is a prominent manufacturer of advanced subsystems designed for high-speed optical networking applications in the telecommunications and information technology sectors. The company specializes in 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, catering to Metro, Regional, and Long Haul optical and data networking markets. CoreOptics advocates for open systems in optical communications networks, enabling efficient data transmission regardless of data rates or fiber types. Their innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is the only field-proven solution available, empowering Tier 1 systems vendors and carriers to enhance their high-performance networks using existing fiber infrastructure. By eliminating the need for Optical Compensators and associated Second Stage Amplifiers, CoreOptics' products can significantly reduce initial deployment costs for customers, making them a valuable partner in the evolution of optical networking.

Clear2Pay is a payments technology company that specializes in delivering innovative solutions for electronic payments processing. The company's Open Payment Framework (OPF) provides financial institutions with the ability to enhance the efficiency of their internal payment systems while offering clients improved services characterized by speed and comprehensive payment information. Clear2Pay's OPF operates within a Service-Oriented Architecture, enabling banks to process payments through a centralized engine that utilizes a library of reusable business services across various payment types. This approach allows financial institutions to integrate new service models with existing infrastructures, ensuring the protection of previous investments while transitioning to a more modern and efficient payment environment. Additionally, Clear2Pay provides a Software Development Kit and a Bank Payment Hub, which offer tools for implementing payment solutions and managing customer interactions, order execution, and dispute processing.

Gemidis is a spin-off company from Ghent University (Belgium) and IMEC (Belgium) and was officially founded in August 2004. Gemidis develops, produces and sells LCOS imagers and driver electronics for both consumer and professional markets.

Welcome Real Time S.A. is a company that specializes in electronic payment software and services, primarily for financial institutions, payment networks, and retailers. Established in 1996 and headquartered in Aix-en-Provence, France, it offers a variety of solutions including credit and debit card acceptance, and integrated value-added services. Key products include XLS Server, which enhances EMV capabilities for payment processing systems; XLS POS, a toolkit for developing payment applications; and XLS Card, which supports card personalization and issuance. Additionally, Welcome Real Time provides CardCare for cardholder services and MerchantCare for merchant activity reporting. With research and development facilities in multiple global locations, the company focuses on creating point-of-sale customer loyalty programs and smart payment device software, along with offering maintenance and marketing consulting services.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. Established in 1992 and headquartered in Berkeley Heights, New Jersey, the company specializes in oral treatments that influence various phases of cell cycle control. Its oncology pipeline features several promising candidates, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently undergoing Phase I trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase (PLK) inhibitor in Phase I trials for advanced leukemias. Additionally, Cyclacel is advancing sapacitabine, an oral nucleoside analogue, in combination studies for patients with BRCA mutations, along with ongoing Phase III trials for acute myeloid leukemia. The company collaborates with the University of Texas MD Anderson Cancer Center to assess the safety and efficacy of its treatments in hematological malignancies and has partnered with ManRos Therapeutics for the development of oral seliciclib capsules aimed at treating cystic fibrosis.

Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.